Vaccine Development
-
Vanderbilt awarded up to $46M through ARPA-H to develop tools against alphaviruses
Jens Meiler, Distinguished Research Professor of Chemistry, was named the principal investigator for the project, in cooperation with 14 investigators across eight institutions. The team will work together to use advanced technology, including computational modeling, AI-driven predictions and structural biology, to develop a groundbreaking vaccine against all alphaviruses that offers long-lasting protection. Read MoreDec 2, 2024
-
Rational vaccine design
Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development. Read MoreSep 22, 2020
-
New tool may speed antibody, vaccine research
Antibody discovery and vaccine development research may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Read MoreDec 12, 2019